Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739930 | 1.00 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL3936793 | 1.00 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL20137871 | 0.98 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL20137760 | 0.98 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL29182805 | 0.98 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL919128 | 0.90 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL13833260 | 0.90 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL1467682 | 0.90 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL512537 | 0.90 | RORC (0.37) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL15285997 | 0.88 | RORC (0.37) | MEN1MAPK1KMT2ARORCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12486273-B2 | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| US-5578604-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-26 | — | — | US | disclosed |
| EP-0641793-B1 | 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | HOKURIKU PHARMACEUTICAL (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5547962-A | QUINOLONE ANTIBIOTICS | HORURIKU SEIYAKU CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| US-5468742-A | Antibacterial agents, feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0671391-A1 | 5-Vinyl- and 5-ethinyl-quinolinone- and -naphthyridone-carboxylic acids | BAYER AG (DE) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0641793-A1 | 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0523512-A1 | 8-vinyl- and 8-ethinyl-quinolone carboxylic acids | BAYER AG (DE) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | MEN1 1837/4885MAPK1 2457/4885KMT2A 1062/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | MEN1 1912/4885MAPK1 228/4885KMT2A 505/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MEN1 166/4885MAPK1 670/4885KMT2A 2720/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | MEN1 34/4885MAPK1 378/4885KMT2A 2624/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MEN1 166/4885MAPK1 670/4885KMT2A 2720/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | MEN1 2177/4885MAPK1 2342/4885KMT2A 884/4885 |
| US-12486273-B2 | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | AQP1, HRH2, HRH1 | MEN1 688/4885MAPK1 1043/4885KMT2A 2046/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | MEN1 4216/4885MAPK1 2873/4885KMT2A 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.